Silodosin
| Evidence Level: L5 | Predicted Indications: 6 |
Table of Contents
Silodosin: Ambras type hypertrichosis universalis congenita
One-Sentence Summary
Silodosin is a selective alpha-1A adrenergic receptor antagonist, originally used to treat benign prostatic hyperplasia (BPH). The TxGNN model predicts it may be effective for Ambras type hypertrichosis universalis congenita, but this is a computational prediction only, with 0 clinical trials and 0 publications currently supporting it.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | Ambras type hypertrichosis universalis congenita |
| TxGNN Prediction Score | 0.9999 |
| Evidence Level | L5 |
| Australia Market Status | Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data |
| Number of PBS Items | 1 (valid: 1) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Silodosin is a selective alpha-1A adrenergic receptor antagonist. It relaxes smooth muscle in the prostate and bladder neck, which eases urinary outflow in BPH. Detailed mechanism of action data is not available in the data compiled for this report, so this description reflects general knowledge of the drug class.
On current evidence, the prediction is not mechanistically convincing. Ambras syndrome is a rare congenital hypertrichosis linked to genomic rearrangements affecting regulation of the TRPS1 gene. This is not an adrenergic pathway, and alpha-1 blockers are not established hair-growth agents. The very high score (0.9999) comes from the TxGNN model (deep learning) and may reflect similarities the model learned between related diseases, not biological evidence.
Other top-ranked predictions show the same pattern. They include hypertrichosis, hair shaft abnormalities, trichomegaly and several congenital malformation syndromes, and none has a clear mechanistic link or any supporting trials or literature.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Australia Market Information
| ARTG Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| ARTG 12077P | Urorec | Capsule 8 mg (oral) | Not available in the data compiled for this report |
Safety Considerations
Safety information is limited in the data compiled for this report. Please refer to the TGA-approved Product Information (PI) for full warnings and contraindications.
- Conditions linked to contraindication or caution (knowledge-graph data, not label text): multiple system atrophy, postural orthostatic tachycardia syndrome, orthostatic hypotension, liver failure, kidney disease, pyoureter, intraoperative floppy iris syndrome.
- Drug Interactions: 99 interactions were identified. Selected examples:
- Major: clarithromycin.
- Moderate: bupropion, aprepitant, morphine, dexamethasone, cimetidine, miconazole, clotrimazole, rolapitant, eliglustat, and the SGLT2 inhibitors (canagliflozin, dapagliflozin, empagliflozin, ertugliflozin).
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction rests only on a score from the TxGNN model (deep learning), which may reflect similarities the model learned between related diseases, not biological evidence. There are no clinical trials or publications, and no plausible mechanistic link between alpha-1A antagonism and the genetic basis of Ambras syndrome. Evidence level is L5.
To proceed, the following is needed:
- A credible mechanistic hypothesis connecting alpha-1A blockade to hair follicle biology or TRPS1-related pathways, supported by preclinical data
- Detailed mechanism of action data for silodosin
- Review of the TGA-approved Product Information for warnings and contraindications (the safety screen cannot proceed without it)
- Any case reports, preclinical studies or registered trials relevant to the predicted indication
- Consideration of whether a rare congenital condition like this is a realistic repurposing target, given the small patient population and the drug’s hypotension and orthostatic effects
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.